Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma

Valeria Lucarini, Carla Buccione, Giovanna Ziccheddu, Francesca Peschiaroli, Paola Sestili, Rossella Puglisi, Gianfranco Mattia, Cristiana Zanetti, Isabella Parolini, Laura Bracci, Iole Macchia, Alessandra Rossi, Maria Teresa D'Urso, Daniele Macchia, Massimo Spada, Adele De Ninno, Annamaria Gerardino, Pamela Mozetic, Marcella Trombetta, Alberto RainerLuca Businaro, Giovanna Schiavoni, Fabrizio Mattei

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Resistance to IFN-I–induced antineoplastic effects has been reported in many tumors and arises, in part, from epigenetic silencing of IFN-stimulated genes by DNA methylation. We hypothesized that restoration of IFN-stimulated genes by co-administration of the demethylating drug 5-aza-2′-deoxycitidine (decitabine [DAC]) may enhance the susceptibility to IFN-I–mediated antitumoral effects in melanoma. We show that combined administration of IFN-I and DAC significantly inhibits the growth of murine and human melanoma cells, both in vitro and in vivo. Compared with controls, DAC/IFN-I–treated melanoma cells exhibited reduced cell growth, augmented apoptosis, and diminished migration. Moreover, IFN-I and DAC synergized to suppress the growth of three-dimensional human melanoma spheroids, altering tumor architecture. These direct antitumor effects correlated with induction of the IFN-stimulated gene Mx1. In vivo, DAC/IFN-I significantly reduced melanoma growth via stimulation of adaptive immunity, promoting tumor-infiltrating CD8+ T cells while inhibiting the homing of immunosuppressive CD11b+ myeloid cells and regulatory T cells. Accordingly, exposure of human melanoma cells to DAC/IFN-I induced the recruitment of immune cells toward the tumor in a Matrigel (Corning Life Sciences, Kennebunkport, ME)-based microfluidic device. Our findings underscore a beneficial effect of DAC plus IFN-I combined treatment against melanoma through both direct and immune-mediated anti-tumor effects.

Original languageEnglish
Pages (from-to)159-169
Number of pages11
JournalJournal of Investigative Dermatology
Volume137
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Interferon Type I
Tumors
Melanoma
T-cells
Genes
decitabine
Neoplasms
Lab-On-A-Chip Devices
Growth
Cell growth
Immunosuppressive Agents
Microfluidics
Antineoplastic Agents
Restoration
Biological Science Disciplines
Adaptive Immunity
Regulatory T-Lymphocytes
Myeloid Cells
DNA Methylation
Epigenomics

Keywords

  • Melanoma
  • Interferons

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma. / Lucarini, Valeria; Buccione, Carla; Ziccheddu, Giovanna; Peschiaroli, Francesca; Sestili, Paola; Puglisi, Rossella; Mattia, Gianfranco; Zanetti, Cristiana; Parolini, Isabella; Bracci, Laura; Macchia, Iole; Rossi, Alessandra; D'Urso, Maria Teresa; Macchia, Daniele; Spada, Massimo; De Ninno, Adele; Gerardino, Annamaria; Mozetic, Pamela; Trombetta, Marcella; Rainer, Alberto; Businaro, Luca; Schiavoni, Giovanna; Mattei, Fabrizio.

In: Journal of Investigative Dermatology, Vol. 137, No. 1, 01.01.2017, p. 159-169.

Research output: Contribution to journalArticle

Lucarini, V, Buccione, C, Ziccheddu, G, Peschiaroli, F, Sestili, P, Puglisi, R, Mattia, G, Zanetti, C, Parolini, I, Bracci, L, Macchia, I, Rossi, A, D'Urso, MT, Macchia, D, Spada, M, De Ninno, A, Gerardino, A, Mozetic, P, Trombetta, M, Rainer, A, Businaro, L, Schiavoni, G & Mattei, F 2017, 'Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma', Journal of Investigative Dermatology, vol. 137, no. 1, pp. 159-169. https://doi.org/10.1016/j.jid.2016.08.024
Lucarini, Valeria ; Buccione, Carla ; Ziccheddu, Giovanna ; Peschiaroli, Francesca ; Sestili, Paola ; Puglisi, Rossella ; Mattia, Gianfranco ; Zanetti, Cristiana ; Parolini, Isabella ; Bracci, Laura ; Macchia, Iole ; Rossi, Alessandra ; D'Urso, Maria Teresa ; Macchia, Daniele ; Spada, Massimo ; De Ninno, Adele ; Gerardino, Annamaria ; Mozetic, Pamela ; Trombetta, Marcella ; Rainer, Alberto ; Businaro, Luca ; Schiavoni, Giovanna ; Mattei, Fabrizio. / Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma. In: Journal of Investigative Dermatology. 2017 ; Vol. 137, No. 1. pp. 159-169.
@article{a8f3bbbc967f4bb09608f9a8574ab023,
title = "Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma",
abstract = "Resistance to IFN-I–induced antineoplastic effects has been reported in many tumors and arises, in part, from epigenetic silencing of IFN-stimulated genes by DNA methylation. We hypothesized that restoration of IFN-stimulated genes by co-administration of the demethylating drug 5-aza-2′-deoxycitidine (decitabine [DAC]) may enhance the susceptibility to IFN-I–mediated antitumoral effects in melanoma. We show that combined administration of IFN-I and DAC significantly inhibits the growth of murine and human melanoma cells, both in vitro and in vivo. Compared with controls, DAC/IFN-I–treated melanoma cells exhibited reduced cell growth, augmented apoptosis, and diminished migration. Moreover, IFN-I and DAC synergized to suppress the growth of three-dimensional human melanoma spheroids, altering tumor architecture. These direct antitumor effects correlated with induction of the IFN-stimulated gene Mx1. In vivo, DAC/IFN-I significantly reduced melanoma growth via stimulation of adaptive immunity, promoting tumor-infiltrating CD8+ T cells while inhibiting the homing of immunosuppressive CD11b+ myeloid cells and regulatory T cells. Accordingly, exposure of human melanoma cells to DAC/IFN-I induced the recruitment of immune cells toward the tumor in a Matrigel (Corning Life Sciences, Kennebunkport, ME)-based microfluidic device. Our findings underscore a beneficial effect of DAC plus IFN-I combined treatment against melanoma through both direct and immune-mediated anti-tumor effects.",
keywords = "Melanoma, Interferons",
author = "Valeria Lucarini and Carla Buccione and Giovanna Ziccheddu and Francesca Peschiaroli and Paola Sestili and Rossella Puglisi and Gianfranco Mattia and Cristiana Zanetti and Isabella Parolini and Laura Bracci and Iole Macchia and Alessandra Rossi and D'Urso, {Maria Teresa} and Daniele Macchia and Massimo Spada and {De Ninno}, Adele and Annamaria Gerardino and Pamela Mozetic and Marcella Trombetta and Alberto Rainer and Luca Businaro and Giovanna Schiavoni and Fabrizio Mattei",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.jid.2016.08.024",
language = "English",
volume = "137",
pages = "159--169",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma

AU - Lucarini, Valeria

AU - Buccione, Carla

AU - Ziccheddu, Giovanna

AU - Peschiaroli, Francesca

AU - Sestili, Paola

AU - Puglisi, Rossella

AU - Mattia, Gianfranco

AU - Zanetti, Cristiana

AU - Parolini, Isabella

AU - Bracci, Laura

AU - Macchia, Iole

AU - Rossi, Alessandra

AU - D'Urso, Maria Teresa

AU - Macchia, Daniele

AU - Spada, Massimo

AU - De Ninno, Adele

AU - Gerardino, Annamaria

AU - Mozetic, Pamela

AU - Trombetta, Marcella

AU - Rainer, Alberto

AU - Businaro, Luca

AU - Schiavoni, Giovanna

AU - Mattei, Fabrizio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Resistance to IFN-I–induced antineoplastic effects has been reported in many tumors and arises, in part, from epigenetic silencing of IFN-stimulated genes by DNA methylation. We hypothesized that restoration of IFN-stimulated genes by co-administration of the demethylating drug 5-aza-2′-deoxycitidine (decitabine [DAC]) may enhance the susceptibility to IFN-I–mediated antitumoral effects in melanoma. We show that combined administration of IFN-I and DAC significantly inhibits the growth of murine and human melanoma cells, both in vitro and in vivo. Compared with controls, DAC/IFN-I–treated melanoma cells exhibited reduced cell growth, augmented apoptosis, and diminished migration. Moreover, IFN-I and DAC synergized to suppress the growth of three-dimensional human melanoma spheroids, altering tumor architecture. These direct antitumor effects correlated with induction of the IFN-stimulated gene Mx1. In vivo, DAC/IFN-I significantly reduced melanoma growth via stimulation of adaptive immunity, promoting tumor-infiltrating CD8+ T cells while inhibiting the homing of immunosuppressive CD11b+ myeloid cells and regulatory T cells. Accordingly, exposure of human melanoma cells to DAC/IFN-I induced the recruitment of immune cells toward the tumor in a Matrigel (Corning Life Sciences, Kennebunkport, ME)-based microfluidic device. Our findings underscore a beneficial effect of DAC plus IFN-I combined treatment against melanoma through both direct and immune-mediated anti-tumor effects.

AB - Resistance to IFN-I–induced antineoplastic effects has been reported in many tumors and arises, in part, from epigenetic silencing of IFN-stimulated genes by DNA methylation. We hypothesized that restoration of IFN-stimulated genes by co-administration of the demethylating drug 5-aza-2′-deoxycitidine (decitabine [DAC]) may enhance the susceptibility to IFN-I–mediated antitumoral effects in melanoma. We show that combined administration of IFN-I and DAC significantly inhibits the growth of murine and human melanoma cells, both in vitro and in vivo. Compared with controls, DAC/IFN-I–treated melanoma cells exhibited reduced cell growth, augmented apoptosis, and diminished migration. Moreover, IFN-I and DAC synergized to suppress the growth of three-dimensional human melanoma spheroids, altering tumor architecture. These direct antitumor effects correlated with induction of the IFN-stimulated gene Mx1. In vivo, DAC/IFN-I significantly reduced melanoma growth via stimulation of adaptive immunity, promoting tumor-infiltrating CD8+ T cells while inhibiting the homing of immunosuppressive CD11b+ myeloid cells and regulatory T cells. Accordingly, exposure of human melanoma cells to DAC/IFN-I induced the recruitment of immune cells toward the tumor in a Matrigel (Corning Life Sciences, Kennebunkport, ME)-based microfluidic device. Our findings underscore a beneficial effect of DAC plus IFN-I combined treatment against melanoma through both direct and immune-mediated anti-tumor effects.

KW - Melanoma

KW - Interferons

UR - http://www.scopus.com/inward/record.url?scp=85006746576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006746576&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2016.08.024

DO - 10.1016/j.jid.2016.08.024

M3 - Article

C2 - 27623509

AN - SCOPUS:85006746576

VL - 137

SP - 159

EP - 169

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 1

ER -